SCHEMBL7201770

SCHEMBL7201770

O=C(NO)C1(O)CNCCC1S(=O)(=O)N1CCC(c2ccccc2F)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 9/20 0.44
ADAM10 O14672 5/20 0.44
MMP9 P14780 2/20 0.44
MMP3 P08254 1/20 0.44
GLRA3 O75311 1/20 0.36
GLRB P48167 1/20 0.36
MMP13 P45452 6/20 0.36
RPLP1 P05386 1/20 0.36
RPLP0 P05388 1/20 0.36
RPS17 P08708 1/20 0.36
RPSA P08865 1/20 0.36
RPS2 P15880 1/20 0.36
RPL35A P18077 1/20 0.36
RPL7 P18124 1/20 0.36
RPL17 P18621 1/20 0.36
RPS4Y1 P22090 1/20 0.36
RPS3 P23396 1/20 0.36
RPS12 P25398 1/20 0.36
RPL13 P26373 1/20 0.36
RPL10 P27635 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7205516 0.88 ADAM10 (0.51) MMP2ADAM10MMP13DRD4HDAC4
SCHEMBL7204290 0.88 MMP2 (0.46) MMP2ADAM10MMP13HDAC4MMP1
SCHEMBL7201786 0.85 MMP2 (0.49) MMP2ADAM10MMP9MMP13DRD4
SCHEMBL7201610 0.85 MMP2 (0.47) MMP2ADAM10MMP9MMP3MMP13
SCHEMBL7204534 0.83 USP5 (0.41) MMP2ADAM10MMP9MMP3MMP13
SCHEMBL7203079 0.83 HTR2C (0.47) MMP2ADAM10MMP13KCNH2ALDH1A1
SCHEMBL7203215 0.83 MMP2 (0.51) MMP2ADAM10MMP9MMP3MMP13
SCHEMBL7200489 0.82 USP5 (0.44) MMP2ADAM10MMP9MMP13KCNH2
SCHEMBL7205353 0.81 CARM1 (0.42) MMP2ADAM10MMP13HDAC4MMP1
SCHEMBL7205659 0.79 TP53 (0.41) MMP2ADAM10MMP9MMP3MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608104-B2 Antiarthritic agents; anticancer agents PFIZER INC 2003-08-19 US disclosed
US-20020019534-A1 Gem substituted hydroxamic acids PFIZER INC. 2002-02-14 US disclosed
EP-1138680-A1 Gem substituted sulfonyl hydroxamic acids as MMP inhibitors Pfizer Products Inc. (US) 2001-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019534-A1 Gem substituted hydroxamic acids MMP14, TOP2A, ADAMTS1 MMP2 13/4885ADAM10 254/4885MMP9 24/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.